Nasdaq
$1.14▲ 1.79%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $131.4MShares out 1.200M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
12- 9.23Regular26.09.24 01:16SCHEDULE 13G/AOwnership#●●●#●●●
Cardiol Therapeutics Inc.
Tejara Capital Ltd has filed a SCHEDULE 13G/A regarding its beneficial ownership in Cardiol Therapeutics Inc. This filing serves to report changes in the investor's equity position and updates relevant corporate governance information.…more
$1.14+1.79%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.23Pre-market26.09.23 19:386-KKey event
Cardiol Therapeutics Inc.
Cardiol Therapeutics has achieved its initial enrollment target of 110 patients for the Phase III MAVERIC trial of CardiolRx ahead of schedule. The steering committee has decided to expand enrollment to up to 150 patients to ensure robust efficacy assessment, shifting the expected topline results to mid-2027. The company confirms that existing capital is sufficient to fund the trial through Q1 2028.…more
$1.14+1.79%vs prev closeView filingShare - 9.16Regular26.09.17 02:47SUPPLOther
Cardiol Therapeutics Inc.
Cardiol Therapeutics has registered a secondary offering of 10,025,000 common shares and 5,012,500 shares issuable upon the exercise of warrants, originally issued in an October 2025 private placement. This registration allows existing selling shareholders to offer and sell these securities from time to time. The company will not receive any proceeds from this offering, and investors should be aware of the potential dilution associated with these shares.…more
$1.14+1.79%vs prev closeView filingShare
11 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.23Pre-market26.09.23 19:02#●●●#●●●#●●●
Cardiol Therapeutics Expands MAVERIC Phase III Trial Enrollment
Cardiol Therapeutics has reached its initial enrollment target for the MAVERIC Phase III trial early but will expand the study to maintain statistical power. Consequently, the topline results are now expected in mid-2027 instead of the first quarter.…more
$1.14+1.79%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.16Pre-market26.09.16 20:28
●●●●●●●● ●●●●● ●●●●●●
Cardiol Therapeutics has secured over $7 million through warrant exercises, extending its cash runway into the first half of 2028. The company also issued an acceleration notice for remaining warrants to streamline its capital structure.…more
$1.14+1.79%vs prev closeShareBenzinga - 9.10After-hours26.09.11 06:02
●●●●●●●● ●●●●● ●●●●●●
Cardiol Therapeutics has filed a base shelf prospectus to potentially raise up to $150 million through various securities offerings. This filing prepares the company for future capital raises, which could lead to shareholder dilution.…more
$1.14+1.79%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report